NVE (NVEC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed, indicating updates or supplemental information for shareholders.
No filing fee required for this submission, suggesting routine or informational content.
Voting matters and shareholder proposals
Proxy materials are being provided to shareholders, likely in advance of an upcoming meeting for voting purposes.
Notice of Internet Availability issued, indicating shareholders can access proxy materials online.
Shareholder rights and capital structure
Shareholders are notified of the availability of proxy materials, supporting transparency and access to information.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NVE
- Quarterly net income rose 27% year-over-year, driven by strong product sales and margin gains.NVEC
Q4 20267 May 2026 - Quarterly revenue up 23% and net income up 11%, with a $1.00 dividend announced.NVEC
Q3 202614 Apr 2026 - Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVEC
Q1 20253 Feb 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, approve pay, and ratify auditor, with focus on ESG and governance.NVEC
Proxy Filing1 Dec 2025 - Key votes on directors, executive pay, and auditor ratification, with strong governance and ESG focus.NVEC
Proxy Filing1 Dec 2025 - Annual Meeting to vote on directors, executive pay, and auditor ratification August 1, 2024.NVEC
Proxy Filing1 Dec 2025